穴位贴敷联合中药治疗围绝经期综合征的系统评价与Meta分析
该系统评价与Meta分析纳入8项RCT共560例围绝经期综合征患者,评估穴位贴敷联合中药的疗效与安全性。结果显示联合组在KMI评分、总有效率、PSQI评分及降低LH方面优于单用中药,KMI评分优于西药组,但所有研究均未报告中药纯度或效价的独立检测。
要点
- 穴位贴敷联合中药可改善围绝经期综合征的KMI评分、睡眠质量及总有效率。
- 联合组降低LH优于单用中药,但对FSH和E2无显著差异。
- 纳入研究均未独立检测中药纯度或效价,且盲法缺失,结论需谨慎解读。
核心结论
- 穴位贴敷联合中药可能提高围绝经期综合征患者的疗效与安全性。
- 因缺乏中药纯度或效价的独立检测及盲法,结果需谨慎解读。
研究设计与样本
- 系统评价与Meta分析,检索8个数据库至2022年8月,纳入8项RCT共560例围绝经期综合征患者。
主要发现
- 联合组与单用中药组比较:KMI评分MD=-2.91(95%CI:-3.91至-1.91),总有效率RR=1.22(95%CI:1.11-1.34),PSQI评分MD=-2.86(95%CI:-3.61至-2.10),LH降低MD=-2.52(95%CI:-4.70至-0.34)。
- 联合组与单用中药组在FSH(MD=-1.66,95%CI:-3.98至0.67)和E2(MD=2.41,95%CI:-0.70至5.52)方面无差异。
- 联合组与西药组比较:KMI评分MD=-6.80(95%CI:-7.95至-5.65),PSQI评分MD=-0.60(95%CI:-1.88至0.68)。
- 联合组总有效率91.7%高于西药组83.49%。
- 所有纳入研究均未报告所用中药产品纯度或效价的独立检测。
关键数值与推荐
- 联合组与单用中药组KMI评分MD=-2.91(95%CI:-3.91至-1.91)。
- 联合组与单用中药组总有效率RR=1.22(95%CI:1.11-1.34)。
- 联合组与单用中药组PSQI评分MD=-2.86(95%CI:-3.61至-2.10)。
- 联合组与单用中药组LH降低MD=-2.52(95%CI:-4.70至-0.34)。
- 联合组与西药组KMI评分MD=-6.80(95%CI:-7.95至-5.65)。
临床怎么用
- 可考虑将穴位贴敷联合中药用于围绝经期综合征以改善更年期指数和睡眠质量。
- 联合方案对LH的降低作用优于单用中药,但对FSH和E2未见显著影响。
- 临床决策时应关注所用中药的纯度与效价,并注意证据受盲法缺失限制。
局限性
- 所有纳入研究均未报告中药产品纯度或效价的独立检测。
- 研究缺乏参与者和研究者的盲法。
- 纳入研究数量较少(8项RCT,560例),结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An increasing number of women suffer from perimenopausal syndrome (PMS) and the global burden of this disease has been steadily rising. Acupoint application therapy and Chinese herbal medicine (CHM) are widely used as effective methods for treating PMS, but the efficacy was inconsistent and the evidence should be summarized by quantitively analysis. OBJECTIVE: The purpose of this systematic review and meta-analysis was to evaluate the clinical efficacy and safety of the acupoint application combined with the CHM for the treatment of PMS. METHODS: We searched eight databases from their inception to August 2022 to identify relevant studies. Only randomized controlled trials (RCTs) focusing on acupoint application combined with CHM for the treatment of PMS were included in this study. To assess the clinical efficacy and safety, meta-analysis was used to quantitively synthesize the effect estimates. Subgroup analysis, publication bias assessment and sensitivity analysis were also performed. We further assessed whether the included studies had reported on the purity and potency of the CHM used in their trials. RESULTS: A total of 8 RCTs with 560 participants were included in the systematic review and meta-analysis, of which none of them included a description of an independent testing of purity or potency of the CHM product used. There were significant differences between the acupoint application combined with CHM and CHM alone in terms of Kupperman Menopausal Index (KMI) score (MD = -2.91, 95%CI: -3.91 to -1.91), total effective rate (RR = 1.22, 95% CI: 1.11-1.34), Pittsburgh Sleep Quality Interview (PSQI) score (MD = -2.86, 95% CI: -3.61 to -2.10) and reduction in the serum level of luteinizing hormone (LH) (MD = -2.52, 95% CI: -4.70 to -0.34), whereas there were no differences between the two groups regarding lowering serum level of follicle-stimulating hormone (FSH) (MD = -1.66, 95% CI: -3.98-0.67) and elevating serum level of oestradiol (E2) (MD = 2.41, 95% CI: -0.70-5.52). For the comparation between the acupoint application combined with CHM and western medicine (WM), the KMI score (MD = -6.80, 95%CI: -7.95 to -5.65) was substantially different, while the PSQI score (MD = -0.60, 95% CI: -1.88-0.68) was not substantially different. The total effective rate in the combined group (91.7%) was higher than the western medicine group (83.49%). CONCLUSION: Acupoint application combined with CHM may enhance the efficacy and safety of patients with PMS. However, due to the lack of description of an independent testing of purity or potency of the CHM product used in the trials, as well as blinding of participants and investigators, these results should be interpreted with caution.
引用
- Xing W, Wang X, Zhu W, et al. Effects of acupoint application therapy combined with chinese herbal medicine on perimenopausal syndrome: A systematic review and meta-analysis of randomized controlled trails. Complement Ther Med. 2023. PMID: 36623609. doi:10.1016/j.ctim.2023.102916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。